Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
memo - Magazine of European Medical Oncology
Erschienen in:

21.08.2017 | comment

Highlights from the 2017 St. Gallen Breast Cancer Consensus

verfasst von: Prof. Dr. Georg Pfeiler, MD, Prof. Dr. Rupert Bartsch, Univ. Prof. Dr. Florian Fitzal, MBA F.E.B.S.

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 3/2017

Einloggen, um Zugang zu erhalten

Excerpt

Three topics on endocrine therapy of pre- and postmenopausal patients with hormone-receptor positive breast cancer were discussed in detail: ovarian function suppression (OFS), aromoatase inhibitors (AI) and extended endocrine therapy. The panel acknowledged that patients below 35 years of age, premenopausal after chemotherapy or with 4 or more involved lymph nodes should receive OFS. …
Vorheriger Artikel Disease control with brentuximab vedotin in an aged patient with primary cutaneous anaplastic large-cell lymphoma
Nächster Artikel New diagnostic tools for breast cancer
Metadaten
Titel
Highlights from the 2017 St. Gallen Breast Cancer Consensus
verfasst von
Prof. Dr. Georg Pfeiler, MD
Prof. Dr. Rupert Bartsch
Univ. Prof. Dr. Florian Fitzal, MBA F.E.B.S.
Publikationsdatum
21.08.2017
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 3/2017
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-017-0349-x

Weitere Artikel der Ausgabe 3/2017

Activity of panobinostat in combination with bortezomib and dexamethasone in advanced, proteasome inhibitor refractory multiple myeloma

  • case report

What’s new in chemotherapy for non-small cell lung cancer?

  • short review

Development of chemotherapeutics in oncology: is there anything new?

  • editorial

New chemotherapies in gastric adenocarcinoma

  • short review

Novel therapeutics in supportive cancer treatment

  • short review

Prognostic significance of aberrant expression of CD markers in acute lymphoblastic leukemia

  • review